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1. Introduction 
In glaucoma, the most commonly used surgical options attempt to establish communication 
between the anterior chamber and the subconjunctival space, either by removing part of the 
trabecular meshwork and thus decreasing resistance to the passage of the aqueous humour 
or by means of drainage tubes that conduct the aqueous humour toward extraocular 
subconjunctival reservoirs. Trabeculectomy is still the most widely performed glaucoma 
procedure worldwide. Nevertheless, it creates an artificial pathway for drainage of aqueous 
that is less optimal than physiologic outflow and is associated with numerous short and 
long-term serious complications. Surgical alternatives, such as deep sclerectomy, are more 
demanding, longer and seem to be surgeon-dependent. Although they achieve a high level 
of hypotensive effect, these forms of surgery are not exempt from potential complications 
and are highly dependent on the inflammatory and healing response of the patient.1 The use 
of antimetabolites to regulate this healing response is also linked to a higher rate of 
complications.2,3,4,5,6 
The interest in new and possibly less invasive surgical techniques to lower intraocular 
pressure is growing. In particular, to avoid the eventual problems linked to surgical trauma to 
the conjunctiva and the ensuing inflammatory response, several new ab interno methods that 
attempt to achieve intraocular pressure control have been developed. Some of these methods 
are aimed at obtaining flow through Schlemm’s canal, whereas others point to the possibility 
of obtaining flow from the anterior chamber to the suprachoroidal space. Gonioscopy is used 
in these ab interno procedures in order to visualize the site of implantation. 
2. Visualizing the trabecular meshwork 
Trabecular bypass surgery can be performed through the same incision used for 
phacoemulsification in cases of combined surgery, or by means of a paracentesis, when it is 
performed as a sole procedure. A temporal incision is warranted because of ease of patient’s 
head positioning. Visualization of the angle using the goniolens should be practiced in cases 
prior to performing surgery, in order to learn the correct techniques. 
In the case of phakic patients, the instillation of a miotic is recommended to minimize the 
risk of lens injury. If the procedure is carried out under topical anaesthesia it is advisable to 
introduce lidocaine 1% into the anterior chamber, because some of the surgical manoeuvres 
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can be uncomfortable for the patient. It is perfectly possible to carry out the surgery under 
topical anaesthesia with intracameral lidocaine; however, when performing the operation 
for the first few times, it may be advisable to use some form of locoregional anaesthetic 
(retrobulbar, peribulbar or sub-Tenon). 
Once the incision has been made in the temporal cornea, the anterior chamber must be filled 
with a cohesive viscoelastic that makes it possible to enlarge the region of the angle where 
surgery is planned. 
A perfect view of the trabecular meshwork and of the angle must be achieved. The most 
common error is failure to position the microscope and/or the patient adequately in order to 
obtain an adequate view of the trabeculum. The patient’s head must be turned 
approximately 45° away from the surgeon. The microscope should be tilted approximately 
30⁰ towards the operating surgeon.  




The iStent® trabecular micro-bypass (Glaukos Corporation, Laguna Hills, CA) is made of 
titanium and coated with heparin (Duraflo® powder). It is L-shaped and measures 1 mm x 
0.33 mm, with a nominal snorkel bore diameter of 120 microns (fig.1). The iStent is designed 
to fit into Schlemm´s canal. The distal portion of the stent is bevelled and sharpened to 
facilitate penetration into the tissue of the trabecular meshwork. The external surface 
features three retention arches that impede the movement of the stent once it has been 
implanted. The implant weighs approximately 0.1 mg. It is delivered preloaded on an 
insertion device (fig.2) and it is implanted at the level of the trabecular meshwork with the 
aid of a Swan-Jacob type goniolens (fig.3). Two versions of the iStent are available; one for 
the right eye and one for the left eye. The difference lies in the orientation of the rails, 
designed to facilitate the penetration of the implant into the trabecular meshwork. The distal 
tip of the implant should point towards the patient’s feet at all times. 
 
Fig. 1. iStent® trabecular bypass 
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Fig. 3. Swan-Jacob goniolens 
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In all these techniques the patient is draped as for cataract surgery. Myosis is warranted if 
the surgery is not combined with phaco. Surgical steps are as follows:  
1. A paracentesis is made generally using a 15 degree blade (fig.4).  
2. If needed, the pupil is constricted with intracameral miotics and a cohesive viscoelastic 
is injected in the anterior chamber.  
3. The tip of the stent, with the distal part parallel to the trabecular meshwork, should 
approach the trabecular meshwork at an angle of 15° to facilitate penetration of  
the tissue (fig.5). The stent should be placed parallel to the plane of the iris with the 
inner part covered by the meshwork and the lumen away from the iris. Excessive 
resistance indicates a path that is too perpendicular to the trabeculum or a wrong 
implantation site. Once the trabecular meshwork covers all of the implant, it should 
be released by pressing the applicator button. Only the proximal end of the stent 
should remain visible in the anterior chamber. The stent can be seated in its final 
position by gently tapping the side of the snorkel with the inserter tip. A small reflux 
of blood from Schlemm´s canal is common and reflects adequate positioning of the 
stent. 
4. At the end of surgery, blood and viscoelastic are removed(Fig.6). The corneal incision 






Fig. 4. A paracentesis is performed temporally.  
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Fig. 5. The iStent is already half way within the trabecular meshwork. 
 
Fig. 6. Residual blood and viscoelastic are washed and aspirated by the anterior chamber 
with a coaxial I/A tip - the same can be done using a bimanual technique. 
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The post-operative suggested treatment should be similar to what is commonly used by 
each surgeon for an uncomplicated phacoemulsification procedure. Generally anti-
glaucoma drugs are discontinued post-operatively and reintroduced if the patient does not 
achieve the target pressure. 
iStent inject is a second generation trabecular bypass device that is also designed to restore 
conventional outflow (fig. 7). Two stents come preloaded in a sterile disposable injector that 
is placed on the meshwork.  A stent release button on the injector is used to release the 
stents one at a time into the proper position (approximately 2-3 clock hours apart (fig. 8). 
This new mechanism of implantation allows for implantation of two stents without exiting 
the inserter from the eye. 
 
Fig. 7. iStent® inject (image provided by Glaukos) 
 
Fig. 8. iStent® inject inserter (image provided by Glaukos) 
3.2 Trabectome 
The Trabectome™ (NeoMedix Inc., Tustin, CA, USA) device consists of a disposable 
handpiece tip (19.5-gauge) that will fit through a 1.6mm corneal incision. The handpiece is 
connected to a console with irrigation and aspiration, and also to a simple electrocautery 
generator. The foot pedal controls the irrigation, aspiration and electrocautery ablation via a 
stepwise foot control similar to a phacoemulsification system (fig. 9).  
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Fig. 9. Trabectome probe and tip 
The tip of the handpiece is specially designed with an insulated footplate and is pointed for 
ease of insertion through the trabecular meshwork into Schlemm´s canal. The footplate is 
coated with proprietary multilayered polymer, which provides thermal stability, mechanical 
strength, biocompatibility and chemical resistance in laboratory testing. The aspiration port 
is in close proximity (approximately 0.3 mm) to the cautery electrode and serves to remove 
debris during ablation. The irrigation is 3 mm from the surgical site and serves the dual 
purpose of keeping the eye pressurized and further dissipating heat energy. Although the 
irrigation and aspiration system role is important, the high-frequency electrocautery 
generator system is the pivotal point of this technology. The generator is a modified 800 EU 
unit from Aaron/Bovie (St. Petersburg, FL, USA) and operates at a frequency of 550 kHz 
with adjustable power setting in 0.1-W increment up to 10 W (recommended range 0.5–1.5 
W). The target tissue is disrupted and disintegrated by applying heat energy in bursts with a 
high-peak power and low duty cycle. This ablation approach equates to high-energy bursts, 
which are bunched into small increments with comparably long time intervals in between. 
As a result, disruption and disintegration of tissue is achieved rather than a thermal-cooking 
effect such as that seen in traditional cautery of blood vessels.7,8 
Surgical steps: steps 1 and 2 are equal to the previous procedure, although a specially 
designed blade is provided by the manufacturer to obtain a water-tight paracentesis. A 
small paracentesis is more important with this procedure because during surgery the 
viscoelastic material is washed out by the water flowing through the tip of the instrument. 
2) The tip of the footplate is inserted through the paracentesis aiming at the trabecular 
meshwork and then it is inserted through the trabecular meshwork into Schlemm´s canal . A 
foot switch activates the aspiration and electro-surgical elements that ablate and remove the 
strip of trabecular meshwork and Schlemm´s canal as the surgeon slowly advances the 
instrument along the meshwork in a clockwise and then counter clockwise direction using 
the insertion site as a fulcrum. A strip of trabecular meshwork and Schlemm´s canal 
spanning 80°–100° is ablated and removed under direct gonioscopic visualization. 
Intraoperative reflux of blood through the resulting cleft is desirable in this procedure and 
confirms appropriate ab interno “unroofing” of Schlemm’s canal. 4) At the end of surgery 
any residual viscoelastic or blood present in the anterior chamber is removed. It is generally 
not necessary to hydrate the paracentesis.  
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The post-operative suggested treatment includes: antibiotics used for prophylaxis. 
Pilocarpine 2% qid should be used starting on the first post-operative medication and 
continued for a month. Lotemax is advised for three weeks and then tapered. Directly post-
operative it is advised to continue the previous pre-operative anti-glaucomatous therapy, 
although prostaglandins should possibly be avoided. .Prof. Baerveldt recommends the 
eventual use of Latanoprost rather than other prostaglandins if they are absolutely 
necessary.  Iopidine and Brimonidine can be used and are generally suggested. Anti-
glaucoma medications can be reduced a month after surgery if target pressure is achieved. 
3.3 Other procedures 
Other approaches of gonioscopic surgery include the Ivantis method which simulates a 
short canaloplasty. 
Two additional devices are aimed at improving flow of the aqueous humor from the 
anterior chamber to the suprachoroidal space. These are the Glaukos iStent supra and the 
Transcend Cypass. These devices will not be discussed, because the current data are less 
than one year post-operative. 
4. Results 
4.1 iStent 
Numerous in vitro and in vivo studies support the stability, the effectiveness and the safety 
of the trabecular bypass iStent. 
In 2004, Bahler demonstrated in vitro that the intraocular pressure was lowered after 
placement of a single stent, from 21.4 +/- 3.8 mm Hg to 12.4 +/- 4.2 mm Hg (P < .001).9 This 
corresponded to an 84% increase in facility of outflow. Eyes receiving more than one stent 
had final IOP of 11.9 +/- 3.7 mm Hg. Nine eyes underwent sequential implantation of 
additional stents and seven of these had a further decrease of IOP (13.6 +/- 4.1 to 10.0 +/- 
4.3; P = .02). This work suggested that bypass of the trabecular meshwork lowers IOP in 
cultured human anterior segments. One stent produced the greatest change in pressure. The 
sequential addition of more stents further lowered pressure in seven of nine eyes. Parallel to 
this study the founders/manufacturers of the iStent evaluated the stability of the implant on 
ex vivo eyes confirming that the L shape of the stent could not be moved even with strong 
traction on the stent itself. 
A small clinical case series (n=6) reaffirmed the potential clinical utility of the current 
titanium version inserted ab interno and provided additional confirmation that the device 
stayed in place and continued to function to lower IOP with fewer medications through 
follow-up of one year.10 All patients were seen day one, week one and at 1, 2, 6 and 12 
months post-operatively. The mean pre-operative IOP of 20.2 ±6.3 decreased and stabilized 
at 14 to15 mm Hg with reduced medications out to one year. All devices remained in place 
and no complications were noted. 
A larger prospective, 24-month, uncontrolled, multicenter, multicountry evaluation of 58 
patients with uncontrolled primary open-angle glaucoma (including pseudoexfoliation and 
pigmentary) evaluated the effectiveness of the concurrent phacoemulsification and stent 
implantation.11 Of the 48 patients in the per protocol population, 42 completed the 12 
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months follow-up. At baseline, mean (+/-SD) intraocular pressure (IOP) was 21.7+/-3.98 
mmHg. At 12 months, mean IOP was reduced to 17.4+/-2.99 mmHg, a mean IOP reduction 
of 4.4+/-4.54 mmHg (p<0.001, 18.3%). At baseline, patients were taking a mean 1.6+/-0.8 
medications. By 12 months, the mean number of medications was reduced to 0.4+/-0.62 
(p<0.001). Half the patients achieved an IOP ≤ 18 mmHg and were able to discontinue 
hypotensive medication by the 12 month visit. The most commonly reported device-related 
adverse events were the appearance of stent lumen obstruction (seven eyes) and stent 
malposition (six eyes). None of the adverse events were deemed serious. 
In 2010 Fea compared in a randomized study the results of phacoemulsification alone vs 
combined surgery (i.e. phacoemulsification and stent implantation).12 The baseline IOP was 
similar in the two groups (combined group: 17.9 +/-2.6; control group: 17.3  +/-3.0 mm Hg) 
with a similar number of medications (2.,0 +/- 0.9 in the combined group and 1.9  +/-0.7 in 
the control group). Post-operative mean IOP at 15 months was 14.8 +/-1.2 and 15.7 +/- 1.1 
respectively in the combined and in the control group (p=0.031). The author demonstrated 
that at 15 months the mean number of ocular hypotensive medications was significantly 
lower in the combined group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007). 
Furthermore, after wash-out of ocular hypotensive medications, IOP was significantly lower 
in the combined group (16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg). These results confirm 
the previous observation that IOP reduction could only partially be attributed to 
phacoemulsification and was in fact enhanced further by implantation of the iStent. The 
same author previously published a case report demonstrating the effectiveness of the 
procedure in one pseudophakic patient.13 
More recently the effect of the iStent on flow was further elucidated by a fluorophotometic 
study by Fernandez-Barrientos et al.14 Thirty-three eyes of 33 patients were randomized to 
either two stents and cataract surgery (n = 17, Group 1) or cataract surgery alone (n = 16, 
Group 2). Before surgery, flow and outflow facility were similar between Groups 1 and  
2 (1.78 +/- 0.44 and 1.74 +/- 0.82 microL/min; P = 0.18; 0.12 +/- 0.03 and 0.13 +/-  
0.06 microL/min/mm H; P = 0.71, respectively). At one year, outflow facility was 
significantly higher in the group with two stents (0.45 +/- 0.27 microL/min/mm Hg in 
Group 1 and 0.19 +/- 0.05 microL/min/mm Hg in Group 2; P = 0.02). 
A larger prospective, randomized, open-label, controlled, multicenter clinical trial with a 
total of 240 eyes with mild to moderate open-angle glaucoma with intraocular pressure 
(IOP) ≤ 24 mmHg controlled on one to three medications compared the results of the 
patients who were randomized to undergo cataract surgery with iStent implantation 
(treatment group) or cataract surgery only (control).15 The primary efficacy measure was 
unmedicated IOP ≤ 21 mmHg at one year. A secondary measure was unmedicated IOP 
reduction ≥ 20% at one year. Safety measures included best-corrected visual acuity (BCVA), 
slit-lamp observations, complications and adverse events. The study met the primary 
efficacy endpoint, with 72% of treatment eyes versus 50% of control eyes achieving the 
criterion (P<0.001). At one year, IOP in both treatment groups was statistically lower from 
baseline values. Sixty-six percent of treatment eyes versus 48% of control eyes achieved  
≥ 20% IOP reduction without medication (P = 0.003). The overall incidence of adverse events 
was similar between groups with no unanticipated adverse device effects. This larger series 
not only further demonstrates the efficacy of the iStent in further lowering the intraocular 
pressure in patients undergoing cataract surgery, but also points out the safety of the 
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procedure. A longer post-operative follow-up through two years was reported more 
recently.16 Best-corrected visual acuity of 20/40 or better was reported in 93% of treatment 
vs. 91% of control eyes at two years. Over the two year period, post-operative adverse 
events occurring at a level of 5% or greater included posterior capsular opacification  
(6% treatment vs. 10% control), elevated IOP (4% vs. 7%, respectively), visual disturbance 
(3% vs. 7%, respectively) and iritis (1% vs. 5%, respectively). Furthermore, in the treatment 
group, stent obstruction and malposition occurred in a small percentage of eyes (4% and 3%, 
respectively) and resolved shortly after occurrence (with or without treatment). The authors 
concluded that the overall long-term safety of iStents implanted during cataract surgery was 
similar to that of cataract surgery alone and that the adverse event/complication rate was 
low through the two year post-operative period. 
4.2 Trabectome 
The results obtained by the Trabectome can be summarized by a single paper which reports 
the experience of the Trabectome group. In this retrospective case series the authors 
reported their experience on follow-up through one year on 143 of 1127 Trabectome surgical 
procedures, including 102 through one year from 738 Trabectome-only and 41 through one 
year from 366 Trabectome-phacoemulsification surgeries17. It should be pointed out that 
many eyes at relatively high risk for filtering surgery failure were included after prior failed 
trabeculectomy or other previous surgeries were included in the study. Considering 
glaucoma surgery only: 273 underwent SLT, 170 ALT, 20 aqueous shunt surgery, 104 
trabeculectomy, five prior Trabectome and five laser iridectomy. 
Considering all cases, mean pre-operative IOP of 23.8 +/- 7.7 mm Hg decreased by 39% to 
16.5 +/- 4.0 mm Hg at 24 months (n = 50). Intra-operative reflux bleeding occurred in 77.6%. 
Medications decreased from 2.8 to 1.2 by 24 months. Sixty-five patients (5.8%) had IOP 
elevation > 10 mm Hg above baseline on day one. Failure led to trabeculectomy in 5.9%  
(n = 67) and shunt installation in 1.6% (n = 18). Kaplan-Meier failure was defined across 
groups with at least two weeks follow-up as IOP > 21 mm Hg with or without medications 
and not reduced by 20% below baseline on two consecutive visits or repeat surgery. For 
Trabectome-only cases, mean preoperative IOP of 25.7 +/- 7.7 mm Hg was reduced by 40% 
to 16.6 +/- 4.0 mm Hg at 24 months (n = 46). No prolonged hypotony, choroidal effusion, 
choroidal haemorrhage or infections occurred. Failure led to trabeculectomy in 8.1% (n = 60) 
and shunt installation in 1.9% (n = 14). Medications decreased from 2.93 to 1.2 by 24 months. 
For Trabectome-phacoemulsification cases, baseline IOP of 20.0 +/- 6.2 mm Hg decreased at 
12 months to 15.9 +/- 3.3 mm Hg (18%) (n = 45) and medications decreased from 2.63 +/- 
1.12 to 1.50 +/- 1.36. Sixteen (4.4%) of 365 had prior failed trabeculectomy and 139 of 365 
(38%) had prior laser trabeculoplasty. 
Although the the large number of patients who underwent surgery of the study are very 
impressive, there are major limitations, including the retrospective nature and the fact that a 
very small number of procedures reported had been followed up postoperatively. Of the 738 
patients who underwent only the Trabectome procedure, only 102 had a one year follow-up 
and of the 366 with combined surgery only 41 were followed up to one year. Furthermore, it 
is not clear if the patients with a longer follow-up and with available data include those high 
risk patients who were originally included in the study. If this is the case it would have been 
very important to analyse if there was any difference in terms of efficacy in the high versus 
low risk patients. 
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Recently, Knape and Smith18 presented the case of a patient who had intra-operative blood 
reflux onto peripheral iris during trabeculectomy 11 months after Trabectome surgery. After 
having left the eye firm after surgery, the author did not report any other episode of hyphema 
during the following period. He hypothesizes that the absence of overlying angle structures, 
including the roof of Schlemm’s canal, may have allowed blood to reflux into the angle and 
onto peripheral iris during a sudden decrease in intraocular pressure in trabeculectomy 
surgery. This self-limited episode suggests that the trabeculotomy remained patent, although 
the patient was not compensated and points out that further studies to assess the 
consequences of permanent trabecular meshwork tissue removal may be warranted. 
More recently, Jea19 reported on a cohort of patients and showed that a previously failed 
Trabectome surgery does not seem to impact the effect of subsequent trabeculectomy. 
5. Complications prevention and treatment 
Bleeding: bleeding with iStent, Trabectome or other trabecular bypass procedures is 
generally minimal, although aspiration of the blood in phakic eyes is suggested in order to 
allow proper visualization.. A very rare occurrence of more significant bleeding in the 
anterior chamber is generally due to damage of the iris either because the surgeon did not 
aim at the correct site or because involuntary movements occurred during surgery. The use 
of air or viscoelastics can stop the haemorrhage. It is generally advisable to postpone the 
trabecular bypass procedure if massive bleeding occurred previously because angle 
visualization can be difficult and because the source of bleeding and the effect on the angle 
structures are easier to visualize after the hyphema has cleared.  
Malposition: the iStent may at times appear malpositioned.  This does not preclude the 
implantation of another one provided the angle can be visualized. It is advisable to move at 
least two or three clock hours away from the previous implant to better visualize the 
meshwork. 
Occlusion: occlusion of the Stent by a seemingly fibrinous plug can sometimes be seen 
during the postoperative follow-up. This may sometimes be eliminated by a single YAG 
laser spot. 
Endothelial damage: although possible, it has never been reported with any of the 
procedures described.  
6. Conclusions 
The idea of approaching the surgery site ab interno is certainly appealing. The opportunity to 
perform a more standardized procedure and the opportunity to preserve the conjunctiva 
and the sites of eventual subsequent surgery are attractive. Furthermore, creating a direct 
communication between Schlemm’s canal and the anterior chamber is a more physiological 
approach to IOP reduction with a lower rate of complications and a faster surgery compared 
to any other available approach. 
Several studies pointed out the efficacy of the iStent in the reduction of IOP, although these 
studies were mainly performed in conjunction with cataract surgery. Nevertheless, there is 
strong evidence both in vitro and in vivo that the stent insertion actually facilitates outflow 
independent of the concurrent phacoemulsification. The procedure is safe and complications 
www.intechopen.com
 
Advances in Ophthalmology 302 
are mainly limited to a small (and transient) blood reflux into the anterior chamber 
immediately upon insertion into Schlemm’s canal. It should be noted, however, that all 
studies were performed in eyes with relatively low pre-operative IOP. At present there is no 
published evidence of the efficacy in patients with severe glaucoma nor what would be the 
impact in patients with higher baseline IOP. 
Upon casual review of the number of cases reported by the papers on the Trabectome and 
the length of the follow-up, it may appear that the evidence of efficacy of this surgical 
method is more stringent. The net IOP reduction seems higher with the Trabectome 
compared to the iStent and patients at higher risk had been treated with this method. 
However, a more accurate analysis of the literature reveals that a very small number of 
patients have been followed for a reasonable amount of time. Futhermore, the ablation of 
part of the trabecular meshwork is certainly a more destructive procedure, although it seems 
that this fact does not impact upon the results of conventional surgery in the limited series 
followed for an adequate postoperative timeframe. 
IOP outcomes with both approaches are usually in the mid-teens. Although mid-teens IOP 
might be adequate for initial and moderate patients, traditional filtering surgery with anti-
fibrotic enhancement and bleb formation will probably remain the principal surgical 
approach to eyes with advanced glaucomatous optic neuropathy. Eventually more 
advanced patients may benefit from trabecular bypass surgery combined with hypotensive 
medications, but too little data are available at present to sustain this approach. Assuming 
ongoing clinical studies continue to be favourable, a strong argument can be made for use of 
these minimally invasive procedures which do not lead to bleb formation nor require anti-
fibrotics, early in the glaucoma injury process, especially considering the difficulties of 
compliance with medical therapy. Neither of these procedures damages the conjunctiva 
superiorly, leaving surgical alternatives where necessary open. Furthermore, continued 
development of suprachoroidal stents (such as the iStent supra and the newer Transcend 
Cypass) may offer additional IOP lowering and thus serve a broader population of patients 
with more advanced disease. 
Given that glaucoma is typically a chronic disease and that the introduction of these 
methods is relatively new, follow-up of the patients at the moment is limited to two years at 
maximum. 
Trabecular surgery requires some learning curve to visualize the angle using a hand-held 
gonioprims and the diffuse illumination of the microscope gives a different appearance of 
the angle’s structures as compared with slit lamp gonioscopy. Furthermore, the need for 
using a hand to hold the gonioprism makes any trabecular surgery strictly bimanual. 
During surgery, the implantation of the iStent is relatively easier compared with the 
Trabectome, because it does not need a continuous circumferential movement and because 
the chamber is well formed with viscoelastics. After the implantation of the device, the 
blood reflux in the anterior chamber is generally minimal with the iStent. 
On the other hand, the Trabectome allows a visual feeling that the trabecular meshwork is 
ablated, whereas it is sometimes difficult to be sure of the correct iStent placement, 
especially when blood cannot be completely washed from the angle. Compared to 
trabeculectomy, additional costs with any device should also be considered. Furthermore at 
present only the Trabectome has been cleared by the FDA, although U.S. FDA approval of 
the iStent is expected in the near future. 
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